LIPOCINE INC. news, videos and press releases - Page 3
For more news please use our advanced search feature.
LIPOCINE INC. - More news...
LIPOCINE INC. - More news...
- LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA APPROVAL OF TLANDO™
- Lipocine Announces Financial Results for the Year Ended December 31, 2021
- Lipocine Announces Regulatory Guidance on LPCN 1144 in Non-cirrhotic NASH
- LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA ACCEPTANCE OF NDA RESUBMISSION FOR TLANDO®
- Lipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO®
- Lipocine to Present Clinical Data on LPCN 1144 at 2022 NASH-TAG Conference
- LIPOCINE ANNOUNCES PATIENT DOSED IN ITS PHASE 2 STUDY WITH LPCN 1148 FOR MANAGEMENT OF LIVER CIRRHOSIS
- Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2021
- Lipocine Announces FDA Grants Fast Track Designation to LPCN 1144 for Treatment of Non-Cirrhotic NASH
- Lipocine Announces Multiple Poster Presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021
- Lipocine to Present at The H.C. Wainwright 5th Annual NASH Investor Conference
- Lipocine Announces FDA Affirmation Of Class 1 NDA Resubmission For TLANDO®
- Lipocine to Present at The Cantor Fitzgerald Virtual Global Healthcare Conference
- Lipocine to Present at The H.C. Wainwright 23rd Annual Global Investment Conference
- Lipocine's LPCN 1144 Met Non-Alcoholic Steatohepatitis ("NASH") Resolution Regulatory Endpoint in Phase 2 LiFT Study
- Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2021
- Thinking about buying stock in Verb Technology, Casper Sleep, Millendo Therapeutics, Lipocine, or Hepion Pharmaceuticals?
- Lipocine Announces Settlement With Clarus Therapeutics
- Lipocine To Present At The Ladenburg Thalmann Healthcare Conference
- Lipocine Announces Presentations at The International Liver Congress™ 2021 Digital Event
- Lipocine To Present At The Raymond James Human Health Innovation Conference
- FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study
- Lipocine to Present at the Lytham Partners Summer 2021 Investor Conference
- Summary Judgment Ruling in Patent Infringement Lawsuit
- Lipocine Announces Financial Results for the First Quarter Ended March 31, 2021
-
Lipocine Inc. - LPCN Stock Chart Technical Analysis for 03-17-2021
- Lipocine Announces Financial Results For The Year Ended December 31, 2020
- Lipocine To Present At M Vest / Maxim Conference And At The Lytham Partners Conference
- Lipocine Announces Publication in Journal of Endocrinological Investigation Highlighting the Potential of LPCN 1144 in the Treatment of NASH and Hepatic Fibrosis
- Lipocine Announces Presentations on TLANDO™ at ENDO 2021 Conference
